HollisterStier Contract Manufacturing, Spokane, Washington, USA, and Draxis Pharma General Partnership, Kirkland , Quebec, Canada, announced today that they have formally aligned the branding of their contract manufacturing & services under the name Jubilant HollisterStier .  This change comes as a part of the  corporate-wide branding alignment by their India-based parent company, Jubilant Life Sciences.  

Jubilant HollisterStier Contract Manufacturing & Services, through individual operating companies in the United States and in Canada, offers high quality contract manufacturing and related services for the global pharmaceutical and biopharmaceutical market, across the full spectrum of clinical and commercial pharmaceutical requirements.  The new name and logo for Jubilant HollisterStier will represent the parenteral, semi-solid and solid dosage manufacturing, development and related services across North America.   

“The change to our branded name and image allows our organizations to more cohesively align with our parent company, Jubilant Life Sciences” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier, Contract Manufacturing & Services.  “Since having been acquired by Jubilant three years ago, we have expanded our service offerings to include multiple dosage forms and services throughout the entire life sciences value chain.  This new name and logo completes our transition and full integration into Jubilant Life Sciences a leading Integrated Pharma & Life Sciences company, and more clearly communicates our breadth of service offerings available through this association”.

About Jubilant HollisterStier Contract Manufacturing & Services

Jubilant HollisterStier Contract Manufacturing & Services (JHSCMS) is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India.  Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. JHSCMS is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and Life Sciences player, headquartered in India. For more information about Jubilant HollisterStier, visit HScontract.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd) is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 65 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2010 stood at US$ 723 Mn. For more info: www.jubl.com

Media Inquiries:

Shannon Jordan, 509.482.4958

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.